Hantz Financial Services Inc. Sells 2,581 Shares of Bruker Co. (NASDAQ:BRKR)

Hantz Financial Services Inc. decreased its position in shares of Bruker Co. (NASDAQ:BRKR) by 66.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,295 shares of the medical research company’s stock after selling 2,581 shares during the quarter. Hantz Financial Services Inc.’s holdings in Bruker were worth $76,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. FMR LLC lifted its position in Bruker by 21.4% in the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after acquiring an additional 2,521,904 shares in the last quarter. Point72 DIFC Ltd raised its stake in shares of Bruker by 4,875.9% in the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company’s stock worth $32,470,000 after purchasing an additional 460,722 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Bruker by 1,933.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock valued at $28,331,000 after purchasing an additional 390,057 shares in the last quarter. State Street Corp boosted its position in shares of Bruker by 9.6% during the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after buying an additional 318,808 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Bruker by 10.8% during the third quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock worth $137,702,000 after buying an additional 193,580 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 28.30% of the stock is currently owned by insiders.

Bruker Price Performance

NASDAQ BRKR opened at $58.15 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The company has a market cap of $8.82 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 3.68 and a beta of 1.17. Bruker Co. has a 52 week low of $48.07 and a 52 week high of $94.86. The firm’s 50-day simple moving average is $58.50 and its two-hundred day simple moving average is $61.28.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. During the same quarter in the previous year, the company posted $0.74 earnings per share. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. Research analysts predict that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.34%. Bruker’s payout ratio is 9.62%.

Analysts Set New Price Targets

BRKR has been the topic of a number of analyst reports. Barclays cut their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Citigroup cut their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company decreased their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. TD Cowen cut their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a report on Thursday, December 5th. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $74.45.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.